Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab

When it comes to Amgen, all eyes are on denosumab. That's as it should be: Amgen's future rides on the potential blockbuster. But investors shouldn't lose sight of Amgen's past and present: how the company manages the continued threats to Aranesp have important lessons for the biopharma sector as a whole-and for denosumab too.